Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Multiple sclerosis: an immune or neurodegenerative disorder?
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Treatment of neuromyelitis optica.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
BTG Commences Phase IIa Study of Multiple Sclerosis
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
Dynamic regulatory network controlling TH17 cell differentiation.
Genetics of multiple sclerosis: swimming in an ocean of data.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?

Pages